Life sciences firm OptiBiotix Health has agreed a three year distribution deal in Russia and Kazakhstan.

The York-based company has partnered with SilvEXPO Ltd for the distribution and commercialisation of its own label CholBiome products which contain its LP strain for reducing cholesterol and blood pressure.

CholBiome products containing LP offer a natural and clinically proven way to help reduce cardiovascular risk factors.

SilvExpo was launched in the pharmaceutical and nutraceutical industry after ten years of scientific work. The company focuses on exporting next generation food supplements to its global partners, supplying countries including France, Armenia, Bulgaria, Vietnam, Korea, Singapore, Malaysia, Russia and Kazakhstan.

The nutraceutical company has now agreed CholBiome will be the first product from ProBiotix Health to be offered and introduced throughout the chain of pharmacies in Russia and Kazakhstan.

The deal grants SilvExpo non-exclusive distribution rights for CholBiome, extending the sales channel for the CholBiome range into Eastern Europe’s largest probiotics markets.

Cardiovascular disease accounts for up to 56% of all deaths in Russia and Kazakhstan, according to the WHO, meaning the two countries have some of the highest mortality rates relating to cardiovascular health in Eastern Europe.

Per Rehné, commercial director of OptiBiotix, said: “We are pleased to announce this agreement which extends the sales channel of our CholBiome products into Russia and Kazakhstan where cardiovascular disease are the leading cause of morbidity and mortality. We chose SilvExpo for its knowledge and speed to market and they have shown the ability to grow product sales in challenging markets.

“This agreement is a strategic step to build the distribution sales channel for CholBiome® products in Eastern Europe and we anticipate that the agreement could produce revenues quickly.”